STARPORT (STAndard Systemic TheRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer)

Eighty-five percent of men with prostate cancer have disease that stays within the prostate gland itself. However, 20% of Veterans who undergo local treatment for prostate cancer (radiation or surgery) will see their cancer return and spread outside the prostate. VA researchers with the STARPORT clinical trial are examining the benefits of combining local therapy with systemic drugs to treat prostate cancer with limited spread. They want to find out if this combination improves disease control compared to drugs alone in Veterans with recurrent prostate cancer. Visit https://clinicaltrials.gov/study/NCT0... for more information.